January 21, 2021 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools

Fluidigm Receives CE-IVD Mark for Its Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19

Jan 21, 2021 SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company has received the CE-IVD mark for its Advanta™ Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.... Read more

January 21, 2021 Chemicals, Reagents & Kits Clinical Research/Diagn. Life Science Tools

Sales of Novel Coronavirus PCR Testing Reagent Kits outside Japan Exports Began

January 21, 2021 Shimadzu Corporation will begin fully rolling out sales of the novel coronavirus (SARS-CoV-2) detection reagent kits outside Japan. On January 19th, Shimadzu obtained provisional authorization from the Singapore Health Sciences Authority (HSA) to sell the kits and will start exporting the kits to Southeast Asian markets through Shimadzu (Asia Pacific) Pte. Ltd.,... Read more

January 20, 2021 Life Science Tools PAI Top-10

QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus

Germantown, Maryland, and Hilden, Germany, January 20, 2021 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections – and will continue to closely monitor their performance as global concerns mount regarding the detection of new viral variants by established... Read more

January 20, 2021 Lab Top-10 Licensing, IP, and Legal Life Science Tools

Illumina Wins Patent Infringement Suit against BGI in the UK

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that the High Court of Justice, Chancery Division, Patents Court, issued a judgment in its favor in the patent infringement suit filed against the BGI Companies, MGI Tech Co. Ltd; Latvia MGI SIA; MGI International Sales Co., Ltd; and BGI Complete Genomics Hong Kong Co., Ltd. The... Read more

January 13, 2021 Clinical Research/Diagn. Life Science Tools

Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio’s highly accurate... Read more

January 13, 2021 Clinical Research/Diagn. Life Science Tools

Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio’s highly accurate... Read more

January 13, 2021 Clinical Research/Diagn. Life Science Tools

Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio’s highly accurate... Read more

January 12, 2021 Life Science Tools M&A, Partnerships

Oxford Nanopore and NVIDIA collaborate to partner the DGX AI compute system with ultra-high throughput PromethION sequencer

Tue 12th January 2021 Oxford Nanopore Technologies and NVIDIA are collaborating this year to integrate the NVIDIA DGX Station A100 into Oxford Nanopore’s ultra-high throughput sequencing system, PromethION.  Partnering the NVIDIA A100 Tensor Core GPU technology with the PromethION device aims to deliver the world’s most powerful sequencer that supports real-time analyses at scale, and... Read more